The Rb/E2F pathway is deregulated in virtually all human tumors. It is clear that, in addition to Rb itself, essential cofactors required for transcriptional repression and silencing of E2F target genes are mutated or lost in cancer. To identify novel cofactors required for Rb/E2F-mediated inhibition of cell proliferation, we performed a genome-wide short hairpin RNA screen. In addition to several known Rb cofactors, the screen identified components of the Mediator complex, a large multiprotein coactivator required for RNA polymerase II transcription. We show that the Mediator complex subunit MED13L is required for Rb/E2F control of cell growth, the complete repression of cell cycle target genes, and cell cycle inhibition.
INTRODUCTION
The retinoblastoma tumor suppressor (Rb) is a critical negative regulator of cellular proliferation that is frequently inactivated in human cancer. 1, 2 In its active form, Rb binds to the members of the E2F family of transcription factors and either suppresses their transactivation function or assembles an active repressor complex.
3 E2F family members are essential regulators of genes required for DNA replication and mitosis. 4 --6 The transcriptional repression functions of Rb/E2F complexes have been shown to reflect the recruitment of transcriptional co-repressors. 3,7 --12 In this manner, multi-protein transcriptional repressor complexes are guided to specific genes via the E2F binding sites in target gene promoters.
The ability of Rb to bind stably to E2F is regulated by phosphorylation. In response to mitogenic stimuli in G 0 , cyclin D/CDK4/6 complexes initiate the phosphorylation of Rb and disrupt Rb/E2F interactions. 1, 5, 6 The alleviation of Rb-mediated repression of E2F enables activated transcription of requisite cell cycle genes and passage through the G 1 --S transition. Deregulated Rb/E2F control of cell proliferation is a common feature of cancer and is underscored by the multitude of observed lesions in human tumors. 1, 2, 6 Loss of Rb, loss of the CDK4/6 inhibitor, CDKN2A, and amplification/overexpression of CDK4 or cyclin D are examples of disruptions of cell growth control seen in human tumors. Importantly, the loss of key mediators of transcriptional repression and gene silencing has also been shown to confer resistance to Rb/E2F-mediated cell cycle arrest and have been observed in human tumors. 13, 14 Previous studies from multiple independent laboratories have clearly implicated the Rb/E2F pathway in the maintenance of a stable cell cycle arrest state and the senescent phenotype in human cells. 15 Cellular senescence was initially observed as a barrier limiting the proliferative capacity of cells in culture. 16 In cultured human cells, the erosion of telomeres at chromosome ends leads to a p53-dependent response that arrests cell cycle progression. 15, 17, 18 In addition to telomere shortening, senescence has been shown to be induced by oncogenic signaling, non-telomeric DNA damage and other cellular stresses. 15, 19 Typically, the levels of CDKN2A are greatly increased, leading to the accumulation of active, hypophosphorylated Rb. Senescent cells characteristically exhibit flat-cell morphology and are positive for senescence-associated beta-galactosidase (SA-b-gal) activity. 20 Additionally, Narita et al. 21 described the formation of senescenceassociated heterochromatic foci at E2F promoters during Ras V12 -induced senescence. Overexpression of the adenoviral E1A protein, which targets Rb and its related family members, bypassed the senescent phenotype, alleviated E2F target gene repression, and blocked the formation of senescence-associated heterochromatic foci. The evidence for senescence as a relevant tumor-suppressive mechanism in vivo is compelling. 15,22 --24 Multiple independent investigators have observed senescence markers in premalignant murine lesions induced by activated oncogenes. 25 --29 Furthermore, human benign melanocytic nevi, premalignant lesions in the development of melanoma, possess multiple characteristics of a senescent phenotype. 29 The loss of cooperating factors required for transcriptional repression and heterochromatin formation initiated by Rb/E2F complexes could represent a mechanism for the progression from benign neoplasia to more advanced malignancies. Here, we performed a genomewide short hairpin RNA (shRNA) screen to identify factors critical in the induction and maintenance of the Rb/E2F-induced growth arrest state.
RESULTS
A screen for Rb/E2F cofactors that maintain cell cycle arrest and senescence induction In an effort to identify essential cofactors in the maintenance of Rb/E2F-mediated cellular senescence, an allele of the large pocket domain of Rb (amino acids 379 --928) that harbors mutations in critical serine and threonine residues, and is thereby refractory to CDK phosphorylation and inactivation (phosphorylation-site mutant-Rb, PSM-Rb) was expressed in the T98G glioblastoma cell line via retroviral transduction. The large pocket domain of Rb has been demonstrated to be the minimal domain required for E2F binding and growth suppression, and for tumor suppression in mouse models. 30, 31 Previous studies have demonstrated that this mutant form of Rb represses transcription of E2F target genes and strongly enforces cell cycle arrest. 32, 33 Indeed, cells infected with PSM-Rb-producing retrovirus fail to undergo DNA replication, as measured by 5-bromo-2-deoxyuridine (BrdU) incorporation when compared with control cells (Figure 1a) . Consistent with prior observations, chronic PSM-Rb expression elicited stable growth arrest and characteristics of the senescent phenotype. After 7 days of hygromycin selection, population of cells expressing PSM-Rb display a flat-cell morphology and are positive for SA-b-gal activity (Figure 1b) .
Based on the stability of the arrest state induced by PSM-Rb expression, we designed a protocol for a genome-wide shRNA screen to identify factors required for the induction and maintenance of the arrest phenotype (Figure 1c) . The retroviral vector, pQCXIH, produces PSM-Rb and the hygromycin-resistance gene on a bicistronic transcript, ensuring that hygromycinresistant cells have not lost PSM-Rb expression. The use of the PSM-Rb allele was intended to reduce the complexity of hits from the screen by (1) eliminating factors that might affect Rb phosphorylation, thereby targeting components of the active Rb/E2F repressor complex, and (2) take advantage of the efficacy of PSM-Rb and the reduced background. Using the Open Biosystems (Lafayette, CO, USA) human pSM2c shRNAmir library (version 1.15), 32 pools of shRNA constructs (B2000 shRNA constructs per pool) were introduced via retroviral transduction into T98G cells expressing the murine ecotropic receptor (T98G-EcoR). As a control, a polyclonal population of T98G-EcoR cells was generated expressing an shRNA targeting firefly luciferase. Following the introduction of PSM-Rb into the 32 polyclonal T98G-EcoR shRNA populations, cells evading cell cycle arrest and senescence induction could be harvested and specific shRNA sequences identified by PCR and sequencing ( Figure 1c ). As predicted, T98G-EcoR cells infected with an shRNA targeting luciferase (shLuc) formed very few colonies upon PSM-Rb introduction compared with control retrovirus (Figure 1d) .
Following the infection of T98G-EcoR populations harboring pools of shRNA clones, cells were selected with hygromycin for 19 --21 days. As shown in Figure 2a , the proliferation of shLuc cells was inhibited, whereas colony outgrowth could be observed more readily in the pooled shRNA populations. Cells were harvested from each shRNA pool population, and genomic DNA was prepared. PCR was performed to amplify candidate shRNAs and the resultant fragments were cloned and sequenced. In all, 20 --30 sequencing reactions were performed from each shRNA pool ( Figure 2b ) and 292 specific candidate gene targets were identified by Human BLAT Search of the UCSC Genome Browser (http://www.genome.ucsc.edu; Supplementary Table 1) .
Validation of the screen: identification of E2F5 With the expectation that the candidate genes included false positives, we initially sought to validate genes known to function in the Rb/E2F pathway. Confirming the success of the shRNA screen design, two sequences were recovered targeting the E2F family member E2F5. E2F5 is known to function with Rb family members to suppress transcription of cell-cycle-regulated genes. 4 To validate these findings, several individual shRNA constructs targeting E2F5 were utilized in the generation of T98G-EcoR polyclonal populations and infected with retroviruses producing PSM-Rb (Figure 2c Table 1 ). Biochemical studies have revealed that ZNF217 exists in large transcriptional repressor complexes with CoREST, histone deacetylases, SIN3B, and CtBP. 34, 35 Previous studies have identified CtIP, a protein known to interact with CtBP, as a direct interaction partner with the pocket proteins, p130 and Rb. 36, 37 The ability of CtBP to repress transcription suggested that Rb/E2F might recruit CtBPcontaining complexes via an interaction with CtIP. To confirm that the loss of ZNF217 impairs the function of PSM-Rb in eliciting cell cycle arrest and senescence, we generated cells expressing shRNA sequences targeting ZNF217. As shown in Figures 3a and b, shZNF217 cell populations formed more colonies in the presence of PSM-Rb than shLuc control cells. As prior studies had identified Rb and p130 as interacting partners of CtIP, we utilized the CDK inhibitor, CDKN2A to assess its potential for inducing growth arrest. The expression of CDKN2A blocks CDK4/6 activity and leads to the accumulation of endogenous pocket proteins (RB and p130) in their hypophosphorylated, active forms. As shown in Figure 3c , shZNF217 cells exhibited substantially greater resistance to CDKN2A expression relative to shLuc cells. To lend further credence to the involvement of the ZNF217 complex in the Rb/E2F-induced senescent phenotype, we established two polyclonal cell lines expressing shRNAs targeting CtBP2, as a core ZNF217 complex has been reported to copurify with CtBP2. 38 As shown in Figure 3d , T98G-EcoR cells expressing shCtBP2 constructs formed colonies in the presence of PSM-Rb expression when compared with shLuc control cells. These data provide evidence that the ZNF217 repressor complex is required for Rb/E2F-mediated cell cycle arrest and senescence.
Discovery of novel Rb/E2F cofactors---identification of Mediator complex subunits
The identification of E2F5 and ZNF217 demonstrated that the screen had the capacity to identify relevant functional Rb cofactors. However, the value of a genome-wide screen is the opportunity for discovery of novel cofactors with unexpected functional associations with Rb. As Rb/E2F recruits large, multisubunit complexes such as SWI/SNF to repress transcription, we hypothesized that individual hits from the screen might represent subunits of a common module. To identify such complexes, we made use of the Ingenuity Pathways Analysis tools to scrutinize the candidate gene products (see Materials and methods). The analysis provided an unbiased means to interpret the data and potentially identify novel biological relationships that could be the basis for further study. Inspection of the individual networks revealed a highly interconnected hub containing six unique gene products that were each identified as independent hits in the shRNA screen (Figure 4a ). Interestingly, the interactions observed between the six gene products (MED13L, MED27, DDX52, ZCCHC10, TARDBP and DNAJA1) were based upon a study designed to elucidate the subunit composition of the Mediator complex. 39 The Mediator complex is comprised of 26 --30 subunits and is collectively required for the activation of RNA polymerase-II-dependent transcription. 40, 41 While MED13L and MED27 are bona fide components of the Mediator complex, the possible role of DDX52, ZCCHC10, TARDBP and DNAJA1 in Mediator function is unclear. Nevertheless, this analysis did suggest the potential role of the Mediator complex components in Rb/E2F-mediated cell growth control.
Initially, we sought to validate that knockdown of MED13L and MED27, as well as DDX52, ZCCHC10, TARDBP and DNAJA1, conferred resistance to Rb/E2F-induced growth arrest. Individual shRNAs targeting these gene products were obtained from the Open Biosystems library, introduced into T98G-EcoR cells, and the resultant populations were subsequently infected with PSM-Rb (Figures 4b and c) . Although additional shRNAs were not available for MED27 and ZCCHC10, multiple shRNA sequences targeting the Mediator-complex-associated proteins conferred resistance to the proliferation arrest induced by active Rb expression (Figures 4b  and c) . Collectively, these findings confirm the role of multiple subunits of the Mediator complex (MED13L and MED27) in Rb/ E2F-induced growth inhibition.
MED13L is a functional Rb/E2F cofactor The various Mediator subunits have been grouped into structural modules: head, middle, tail and kinase modules. The kinase, or CDK8, module contains the MED12, MED13, CDK8 and Cyclin C subunits. 40, 41 The function of MED13L is less understood, but sequence homology and biochemical data support its classification as a Mediator subunit. 39, 42 We first sought to determine whether the knockdown of MED13L might be required for the induction of the senescent phenotype by Rb/E2F. T98G cells (control) and polyclonal population of T98G cells expressing a control shRNA or shRNA sequences targeting MED13L were infected with retrovirus producing PSM-Rb. Approximately 3 weeks after infection, the cells were fixed and processed to detect SA-b-gal activity (Figure 5a ). Consistent with expectation, the colonies formed in shMED13L T98G populations were negative for SA-b-gal activity. To confirm the requirement for MED13L in Rb/E2F-mediated growth arrest in normal cells, we introduced the shLuc and shMED13L constructs into a diploid fibroblast cell line (human foreskin fibroblast, HFF) via retroviral transduction. Cells were then infected with retrovirus producing CDKN2A and selected with hygromycin for 19 days. Strikingly, each of the shMED13L HFF populations exhibited resistance to CDKN2A-mediated growth arrest when compared with shLuc cells (Figure 5b ). To determine whether MED13L had a functional role in PSM-Rbmediated repression, we examined endogenous protein levels of cyclin A, a critical Rb/E2F target gene induced at G1/S of the cell cycle. Previous work has demonstrated that cyclin A overexpression could bypass the inhibition of DNA synthesis by PSM-Rb. As further validation that MED13L functions as a requisite cofactor in the Rb/E2F-mediated repression of the cyclin A gene, we made use of a reporter construct under the control of the cyclin A promoter. Using the U2OS cell line, a control siRNA pool or an siRNA pool targeting MED13L, the reporter construct containing the cyclin A (-608CycA-Luc) promoter driving firefly luciferase expression, and a Renilla luciferase expression plasmid were introduced by transient transfection (Figure 5d ). Forty-eight hours later, cells were infected with adenovirus producing GFP as a control, or GFP and PSM-Rb. Twenty-four hours after adenoviral infection, luciferase activity was assessed. As shown in Figure 5d , although the cyclin A reporter activity could be repressed by PSMRb in the presence of control siRNA, the depletion of MED13L interfered with the attenuation of cyclin A activity in response to PSM-Rb. Taken together, these data demonstrate that MED13L is essential for the complete Rb/E2F-mediated attenuation of cyclin A promoter activity and endogenous protein level.
Given the data indicating a requirement of MED13L for Rb/E2F-mediated transcriptional repression of a G1/S gene encoding an important replication activity, we addressed the possibility that MED13L was similarly required by Rb to block cell cycle progression. As shown in Figure 5e , U2OS cells transfected with siRNA pools targeting luciferase as a control or MED13L were subsequently infected with control adenovirus producing GFP or GFP and CDKN2A. Twenty four hours post infection, cells were labeled with BrdU for 16 h to monitor DNA synthesis. Cells treated with control siRNA were strongly inhibited for BrdU incorporation by CDKN2A expression (Figure 5e ). In contrast, the siRNAmediated knockdown of MED13L blocked the ability of CDKN2A to fully inhibit S-phase progression. These data indicate that the depletion of the Mediator subunit MED13L interferes with the function of the Rb/E2F pathway in the induction of senescence, transcriptional repression and cell cycle arrest.
DISCUSSION
The importance of cell proliferation control by the Rb/E2F pathway has been well established, as disruption of this control is common in human cancer. Although Rb is frequently targeted in cancer, the loss of critical cofactors in Rb/E2F-mediated transcriptional repression has been observed in human tumors. For example, the SWI/SNF chromatin-remodeling complex cooperates with Rb to repress transcription and loss or reduction of expression of multiple subunits has been reported in tumor samples. 3, 14 In addition, cofactors that mediate the formation of heterochromatin at Rb/E2F target promoters, such as the histone methyltransferase Suv39H1, are important in tumor suppression. In Em-myc transgenic mice heterozygous for Suv39H1, T-cell lymphomas develop wherein SUV39H1 expression is lost. 25 There is growing evidence that the senescent phenotype, initially observed in tissue culture cells, is induced in vivo in an Rb-dependent manner and acts as a protective barrier to tumor progression. A recent study has further illuminated the unique aspects of Rb function versus p107 and p130 in cellular senescence. 44 Our intent here was to expand our understanding of Rb/E2F function so as to identify additional functional components that might be contributing to oncogenic phenotypes.
The design of our shRNA screen included the use of an ectopically produced PSM-Rb to elicit stable cell cycle arrest that exhibits a senescent phenotype. As demonstrated by the 
BrdU positive (%) identification of E2F5, the screen was indeed effective in identifying critical Rb-binding partners. In addition, we identified multiple genes known to be important for the induction of cellular senescence, such as p27Kip1, CCAAT/enhancer binding protein beta and RUNX1 45 --49 (Supplementary Table 1 ). Although we were able to validate the shRNA screen via confirmed hits with logical, or even well established, roles in senescence induction and maintenance, further analysis uncovered novel links between Rb and repressor complexes. For example, ZNF217 has been purified in complexes with CtBP1, LSD1, CoREST, and other chromatin-modifying factors. 34, 35, 50 Previous work from our laboratory had identified CtIP as an important binding partner of Rb and the related p130. 36, 37 The knockdown of ZNF217 and a known component of the 'ZNF217 complex,' CtBP2, resulted in an equivalent phenotype. Recently, Krig et al. 51 performed chromatin immunoprecipitation analysis in multiple cell lines to identify ZNF217-binding sites in several tumor cell lines. In the embryonal carcinoma cell line, Ntera2, ZNF217 and CtBP2 were detected at numerous promoters and the depletion of ZNF217 led to the upregulation of a specific subset of genes. Interestingly, ZNF217 has been proposed as a candidate oncogene in ovarian and breast cancer. 38 Overexpression of ZNF217 can immortalize human mammary epithelial cells and its depletion in certain contexts can induce sensitivity to doxorubicin and reduce the growth and invasive capacity of an ovarian tumor cell line. 52 --54 The reconciliation of these studies with the apparent role of ZNF217 in transcriptional repressor complexes will be the subject of ongoing study.
Although the Mediator complex was initially thought to be a general required component for RNA polymerase II transcription, recent studies have elucidated the importance of several subunits in promoter-specific regulation. The presence of the CDK8 module can confer promoter-specific transcriptional repression or activation in a context-dependent manner.
55 --57 Specifically, Donner et al. 55 showed that CDK8, MED12 and Cyclin C were recruited to the p21Cip1 promoter concurrent with its strong transcriptional activation. Furthermore, CDK8 association with multiple p53-responsive promoters correlated with strong transcriptional activity. In contrast, recent studies have demonstrated that MED12 is important in the repression of neuronal genes. Mutations in MED12 are associated with X-linked mental retardation disorders and these disease-associated mutations were shown to abrogate MED12-mediated repression. 58 Interestingly, MED13L was identified as a gene harboring missense mutations and translocations in patients with transposition of the great arteries, a congenital heart defect. 42 However, the effect of these mutations on MED13L transcriptional function has yet to be determined.
A connection between Mediator complex subunits, transcriptional control and cancer was recently reported by Firestein et al. 59 who showed that CDK8 is amplified in human colorectal cancer and exhibits oncogenic properties. CDK8 was required for the activation of genes regulated by b-catenin, a pathway frequently activated in colorectal tumors. In a parallel study, Morris et al. 60 shed light on the observation that colorectal tumors paradoxically tend to retain Rb during tumorigenesis. E2F1 was shown to strongly inhibit b-catenin activity, whereas both CDK8 and RB are able to oppose this function of E2F1. These studies provided impetus to more thoroughly investigate possible connections between Mediator complex subunits and cancer. Here, we examined the contribution of the putative Mediator subunit MED13L to Rb/E2F function. We observed a requirement of MED13L for the full repression of the cyclin A levels and effective growth suppression by an activate Rb/E2F pathway. Consistent with this observation, Mediator has been proposed to confer promoter specificity and subunit composition may be a critical element of that control. 61 Interestingly, the MED24 subunit has been recently identified as an essential gene product in the programmed cell death of the larval salivary gland during Drosophila development. 62 This finding raises the obvious hypothesis that MED24 might have a role in apoptosis in human cells and its loss may promote tumorigenesis.
Collectively, our findings support the notion that disparate Mediator complex subunits have important contributions in a multitude of transcriptional signals. Moreover, further work is imperative to further elucidate their contribution to specific gene promoter activity, the subunit composition of specific Mediator complexes, and their potential significance in carcinogenesis. We present a functional screen for requisite cooperating factors in the cell cycle arrest program enforced by active Rb/E2F signaling. Based on this study, we submit that MED13L functions as a novel cofactor for Rb/E2F-mediated transcriptional repression and cell cycle arrest.
MATERIALS AND METHODS
Cell culture and plasmids T98G cells expressing the murine ecotropic receptor (T98G-EcoR) were provided by J DeCaprio (Dana-Farber Cancer Institute, Boston, MA, USA). T98G-EcoR cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 200 mg/ml G418. HFF and U2OS cells were maintained in DMEM supplemented with 10% FBS. Plat-E (ecotropic) and Plat-A (amphotropic) retrovirus packaging cells were provided by T Kitamura (University of Tokyo) and cultured in DMEM supplemented with 10% FBS, 10 mg/ml blasticidin, and 1 mg/ml puromycin. 63 The large pocket domain of Rb harboring mutations in the relevant CDK sites (PSM-Rb) was provided by E Knudsen (Kimmel Cancer Center, Philadelphia, PA, USA) and has been previously described. 32, 64 PSM-Rb and CDKN2A were subcloned into the pQCXIH plasmid (Clontech, Mountain View, CA, USA). Individual Open Biosystems shRNA constructs were obtained either from the Duke RNAi Facility or directly from Open Biosystems.
Retroviral infections
To generate T98G-EcoR cells containing the Open Biosystems shRNA library (v.1.16), individual shRNA constructs were divided into pools (B2000 clones per pool) and 10 mg of each pooled plasmid DNA preparation was transfected into Plat-E ecotropic packaging cells using Lipofectamine 2000, according to manufacturer's instructions. Approximately 40 h post transfection, retroviral supernatant was collected, filtered using 0.45-mm HT Tuffryn syringe filters, and used to infect T98G-EcoR cells in the presence of 8 mg/ml polybrene. Forty-eight hours post infection, cells were selected with 2.5 mg/ml puromycin. Individual Open Biosystems shRNA constructs (Supplementary Table 2 ) were used to infect T98G-EcoR cells in a similar manner. HFF cells were infected as above, using Plat-A amphotropic packaging cells, and selected in 1.25 mg/ml puromycin. Twenty-four hours post infection with pQCXIH-CDKN2A or pQCXIH-PSMRb, cells were selected with 200 (HFF) or 500 mg/ml (T98G-EcoR) hygromycin.
Adenovirus infection
The cDNAs encoding PSM-Rb and CDKN2A were cloned into pAdTrackCMV plasmid. The pAdTrackCMV-PSM-Rb and pAdTrackCMV-CDKN2A constructs were recombined with pAdEasy-1 and used to generate recombinant adenovirus as previously described.
65 U2OS cells were infected with GFPproducing, GFP and PSM-Rb-producing, or GFP and CDKN2A-producing adenovirus at a calculated multiplicity of infection of B50 (infection efficiency was 95 --100% as determined by GFP fluorescence) and harvested 24 h post infection for western blotting or for 48 h for analysis of BrdU incorporation.
shRNA screen and candidate gene identification T98G-EcoR cells stably expressing pooled shRNAs were infected with pQCXIH-PSM-Rb as described above. Approximately 19 --21 days post infection, surviving cells were collected and genomic DNA isolated using Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA), according to manufacturer's protocol. Genomic DNA (200 ng) was amplified by PCR (30 cycles, forward primer: 5 0 -GGGCCTATTTCCCATGATT-3 0 and reverse primer: 5 0 -GCCTCAAAATGTTCTTTACGAT-3 0 ) and the resultant products purified using Qiaquick Gel Extraction kit (Qiagen). PCR products were cloned using TOPO TA cloning kit (Invitrogen, Grand Island, NY, USA) according to the manufacturer's protocol and at least 30 clones from each reaction were sequenced using M13rev primer, and the target sequence was identified using UCSC Genome Browser.
Senescence-associated b-galactosidase assay Cells were cultured in 6-cm dishes were fixed and stained using the Senescence b-galactosidase Staining Kit (Cell Signaling, Danvers, MA, USA) according to the manufacturer's protocol.
Colony formation assay Approximate 3 Â 10 5 cells were seeded onto 60-mm dishes and infected with retroviruses, as indicated, 24 h later. Cells were washed with phosphate-buffered saline (PBS), fixed with ice-cold methanol for 10 min, stained with 0.5% crystal violet (in 25% methanol) for 10 min and rinsed with double-distilled water. Images were collected using a Fotodyne digital imaging system (Fotodyne, Hartland, WI, USA). The number of colonies per dish was counted and reported relative to control. Statistical significance was assessed using Student's t-test.
BrdU incorporation and immunofluorescence
Four days post selection, cells grown on 25-mm glass coverslips were labeled with 10 mM BrdU for 16 h, washed in PBS, fixed in 3.7% formaldehyde in PBS. DNA was denatured by incubating the coverslips in 1.5 N HCl for 15 min. Coverslips were washed with PBS and permeabilized in 0.5% Triton X-100 in PBS for 20 min. Anti-BrdU antibody (GE Healthcare, Piscataway, NJ, USA) was used according to manufacturer's instructions, and incorporated BrdU was detected using Texas-Red antimouse IgG (Vector, Burlingame, CA, USA). Nuclei were counterstained with Hoechst 33342 (Invitrogen). At least 200 nuclei were counted for BrdU staining per condition.
siRNA transfection U2OS cells were plated on 6-cm dishes and transfected with 25 nM siGENOME Non-targeting siRNA pool #2 (Dharmacon, Lafayette, CO, USA, Dharmacon cat. #D-001206-14 --05) or siMED13L siGENOME SMARTpool (Dharmacon cat. #M-027126-01 --0005) using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer's protocol. Forty-eight hours post transfection, cells were infected with adenovirus as described above.
Protein extraction and immunoblotting U2OS cell pellets were lysed in ice-cold radioimmunoprecipitation assay buffer (50 mM Tris, pH 8.0; 0.1% SDS; 150 mM NaCl; 1% Nonidet P-40 and 0.5% sodium deoxycholate) supplemented with protease inhibitor cocktail (Complete Mini, Roche Indianapolis, IN, USA). Samples were sonicated and insoluble material was pelleted by centrifugation. Protein concentration was determined by BCA Protein Assay (Thermo Scientific, Waltham, MA, USA) and equal amounts of total protein were separated by SDS --polyacrylamide gel electrophoresis, transferred to Immobilon-P PVDF membrane (Millipore, Billerica, MA, USA), and blocked in 5% milk in TBS-T buffer. Primary antibodies used to detect cyclin A (sc-751), CDK4 (sc-601) and Rb (sc-50) were from Santa Cruz (Santa Cruz, CA, USA). MED13L antibody (A302-420A) was from Bethyl Laboratories (Montgomery, TX, USA). Secondary antibody used was goat anti-rabbit IgG coupled to horseradish peroxidase (Thermo Scientific) and detected using enhanced chemiluminescence Western Blotting Detection Reagents from GE Healthcare.
Reporter assays U2OS cells were transfected with 25 nM siRNA, -608-Cyclin A-Luc (provided by E Knudsen), and 5 ng CMV-Renilla (Promega, Madison, WI, USA) using Gene Juice transfection reagent (EMD Biosciences, San Diego, CA, USA) according to the manufacturer's protocol. Forty-eight hours post transfection, cells were infected with adenovirus as described above. Twenty-four hours post infection, cells were harvested and luciferase activity was measured using the Dual Luciferase Assay Kit (Promega), with firefly luciferase activity normalized against Renilla luciferase activity.
Ingenuity pathways analysis
As an initial query, the 292 Gene IDs corresponding to the genes identified in the screen were used to search the Ingenuity pathways database (http://www.ingenuity.com). Interactions were viewed as a single merged network or as individual networks.
